AZ sells rare cancer drug to Sanofi
This is a much lower prediction than the blockbuster figures originally touted, when the drug was also being investigated for non-small cell lung cancer. The drug however failed to succeed in clinical trials involving this patient population ...
PMLiVE - Mon, 27 Jul 2015 00:52

AstraZeneca sells cancer drug to Sanofi for $300m | IFA Magazine – Independent
Press Examiner - Wed, 29 Jul 2015 05:56

Sanofi to buy AstraZeneca's cancer drug for upto $300 mn
Rapid News Network - Tue, 28 Jul 2015 16:48

Lung Cancer Therapeutics Market: Global Industry Analysis, size, share and ...
Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to 90% of all lung cancers. Based on the cell shape and size, NSCLC is ... (blog) - Fri, 24 Jul 2015 08:45

Navidea Awarded $1.7 Million Fast Track NIH SBIR Grant for Evaluation of ...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea announces the receipt of an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.7 million from the National Institutes of Health's (NIH) National ...
Business Wire (press release) - Wed, 29 Jul 2015 04:26

Exelixis: A Buyout Target In The Making
Exelixis announced July 20 positive top-line results from METEOR, the Phase 3 pivotal trial of cabozantinib (Cometriq) for metastatic renal cell carcinoma (RCC). The study .... As a result, I believe the risk of an additional near-term dilution is ...
Seeking Alpha - Mon, 27 Jul 2015 11:58

CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer
Furthermore, the TGFβ1 level was significantly correlated with angiogenesis, tumor progression and prognosis in patients with non-small-cell lung cancer. In advanced tumors, TGFβ signaling pathways are severely deregulated and result in the loss of ... - Mon, 27 Jul 2015 02:56

NivoPlus Clinical Trial Currently Recruiting Patients With Advanced Cancer
Nivolumab has been approved by the FDA for the treatment of advanced melanoma in December 2014 and metastatic squamous non-small cell lung cancer in March 2015. Its combination with chemotherapeutic drugs is expected to activate the body's ...
Immuno-Oncology News - Tue, 30 Jun 2015 05:25

Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers
These carcinogens induce a mutational burden that results in a diverse landscape of neoantigens for immune system-based targeting.3 These characteristics parallel those of non–small cell lung cancer (NSCLC), where pembrolizumab has shown activity in a ...
OncLive - Fri, 24 Jul 2015 07:15

Research report explores the Lung Cancer Surgery Market for the forecast ...
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two major types of lung cancer classified on the basis of microscopic observation. NSLC accounts for around 80% of the lung cancers whereas SLC accounts for the remaining ... (blog) - Fri, 17 Jul 2015 11:12

<-   1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014